Chemiluminescent immunoassay (ChLIA) screening test for the determination of a mix of eight anti-nuclear autoantibodies (ANA), to support the diagnosis and differentiation of systemic autoimmune rheumatic diseases (SARD).
Test for the determination of a mix of 11 human autoantibodies of the immunoglobulin class IgG against nuclear antibodies (ANA), to support the diagnosis and differentiation of systemic autoimmune rheumatic diseases (SARD).
Test for the quantitative determination of soluble CD163 (sCD163; Soluble Cluster of Differentiation 163), which is considered a potential biomarker of renal inflammation in autoimmune diseases with glomerular involvement.
Test for the determination of human antibodies of the immunoglobulin class IgG against phenylalanyl-tRNA synthetase (anti-Zo), to support the diagnosis of systemic autoimmune rheumatic diseases (SARD), particularly myositis.
Test for the determination of human antibodies of the immunoglobulin class IgG against zinc transporter 8 (ZnT8), to support the diagnosis of type 1 diabetes.
Test for the determination of human antibodies of the immunoglobulin class G against the U1 snRNP antigen, to support the diagnosis of systemic autoimmune rheumatic diseases (SARDs), particularly mixed connective tissue disease (MCTD).
Test for the determination of human antibodies of the immunoglobulin class A against the tissue transglutaminase antigen, to support the diagnosis and monitoring of coeliac disease.
Test for the determination of human antibodies of the immunoglobulin class IgG against transcription intermediary factor 1 gamma (TIF1γ), to support the diagnosis of systemic autoimmune rheumatic diseases (SARD), particularly in myositis.
Subscribe to our newsletter to be always updated.